ArticleInflammopharmacology2026
Alkaloid fraction of Duguetia furfuracea demonstrated anti-inflammatory and antinociceptive effects through decrease of tumour necrosis factor alpha in mice models.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Duguetia furfuracea, popularly known as "araticum-seco," is traditionally used in folk medicine for the treatment of pain and inflammatory disorders. This study aimed to analyze the chemical composition and investigate the anti-inflammatory and antinociceptive activities of the alkaloid fraction obtained from the leaves of D. furfuracea (DfFAlk). The chemical composition of DfFAlk was characterized using ultra-fast liquid chromatography (UFLC) coupled with mass spectrometry (UFLC/ESI). In vivo anti-inflammatory activity was assessed using the carrageenan-induced paw oedema model. The effects of DfFAlk on polymorphonuclear leukocyte recruitment and tumor necrosis factor alpha (TNF-α) levels were also evaluated in mouse footpads. In addition, the antinociceptive effect was investigated using the abdominal writhing test, formalin test, and thermal hyperalgesia models, and motor and balance performance were assessed using the rota-rod test. Thirty-four alkaloids were annotated belonging to the aporphine, tetrahydroprotoberberine, benzyltetrahydroisoquinoline, tetrahydroisoquinoline, (bis)benzyltetrahydroisoquinoline, and proaporphine classes. Oral treatment with DfFAlk (100 and 300 mg/kg) significantly inhibited paw oedema, from 2 to 6 h post inflammatory stimulus. The alkaloid fraction (300 mg/kg) attenuated the tissue inflammatory infiltrate 4 and 6 h after carrageenan injection, and decreased TNF-α production, 4 h post carrageenan. The fraction (300 mg/kg) also significantly attenuated the acetic acid-induced writhing response and the formalin-induced licking in both phases. Furthermore, in the hot-plate model, the DfFAlk (300 mg/kg) increased the latency to response from 1 to 3 h after oral treatment. Additionally, DfFAlk-treated mice did not show any alteration of motor and balance performances. The data indicate that DfFAlk has anti-inflammatory and antinociceptive activities.
Indexed as
Identifiers
41489805What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.